Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
Authors' conclusion
Tirzepatide may be an effective treatment for patients with lipodystrophy.
Study context
- Population
- Patients with lipodystrophy who received tirzepatide clinically; FPLD aged 30–74 years, 12 female and 2 male14 FPLD
- Participants
- 17 patients
- Exposure
- Tirzepatide, before vs after treatment
- FPLDn = 14
- Rarer lipodystrophyn = 3
- Outcome
- Change from baseline in metabolic parameters with tirzepatide
- Follow-up
- Median 8.7 months
Methodological detailswithin ongoing natural history studies
- Within ongoing natural history studies
Main finding
As reported in the abstract
BMI significantly reduced, median difference (range, −5.9 to 0.9 kg/m²; P = 0.008)
−1.7
HbA1c significantly reduced, median difference (range, −6.3% to −0.1%; P < 0.001)
−1.1%
TG significantly reduced, median difference (range, −3,820 to 43 mg/dL [−43.2 to 0.49 mmol/L]; P = 0.003)
−65 mg/dL
−0.73 mmol/L
Total daily insulin requirements significantly reduced, median difference (range, −315 to 0 units/day; P = 0.002)
−109
Observational data: associations, not effects.
Further findings
Response in rarer lipodystrophy forms
- Robust response to tirzepatide (atypical PL, acquired GL; aged 35-64 years; all female)
Safety
- Side effects limited to benign gastrointestinal symptoms
Original publication
Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option? Diabetes Care. Published 10 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →